Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridinilazole vs Fidaxomicin for C. difficile Infection
NCT02784002Phase 2Completed
- Sponsor
- Summit Therapeutics
- Start
- Dec 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ridinilazole in Clostridioides difficile infection (CDI), sponsored by Summit Therapeutics. Started Dec 2014; status: completed.
02
Drugs
ridinilazole
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02784002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784002.